Statistics in Biopharmaceutical Research
E728774
Statistics in Biopharmaceutical Research is a peer-reviewed journal focusing on the development and application of statistical methods in pharmaceutical, biotechnology, and medical product research.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Statistics in Biopharmaceutical Research canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T8349475 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Statistics in Biopharmaceutical Research Context triple: [American Statistical Association, publishes, Statistics in Biopharmaceutical Research]
-
A.
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
-
B.
WHO Collaborating Centre for Drug Statistics Methodology
The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
-
C.
Office of Biostatistics
The Office of Biostatistics is a specialized FDA unit that provides statistical expertise and evaluation for drug development and regulatory decision-making.
-
D.
ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
-
E.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Statistics in Biopharmaceutical Research Target entity description: Statistics in Biopharmaceutical Research is a peer-reviewed journal focusing on the development and application of statistical methods in pharmaceutical, biotechnology, and medical product research.
-
A.
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
-
B.
WHO Collaborating Centre for Drug Statistics Methodology
The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
-
C.
Office of Biostatistics
The Office of Biostatistics is a specialized FDA unit that provides statistical expertise and evaluation for drug development and regulatory decision-making.
-
D.
ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
-
E.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
academic journal
ⓘ
scientific journal ⓘ |
| academicDiscipline |
biopharmaceutical research
ⓘ
biostatistics ⓘ statistics ⓘ |
| aimsTo |
advance statistical practice in biopharmaceutical research
ⓘ
bridge methodology and practice in pharmaceutical statistics ⓘ |
| fieldOfStudy |
biotechnology
ⓘ
medical product research ⓘ pharmaceutical statistics ⓘ |
| focusesOn |
application of statistical methods
ⓘ
biotechnology research ⓘ development of statistical methods ⓘ medical product development ⓘ pharmaceutical research ⓘ |
| hasAbbreviation | SBR NERFINISHED ⓘ |
| hasContentType |
case studies
ⓘ
original research ⓘ reviews ⓘ tutorials ⓘ |
| language | English ⓘ |
| medium |
online
ⓘ
print ⓘ |
| peerReviewed | true ⓘ |
| publishes |
applied statistical studies
ⓘ
methodological papers ⓘ research articles ⓘ |
| subjectArea |
Bayesian methods in drug development
ⓘ
adaptive designs in clinical trials ⓘ bioequivalence ⓘ biologics ⓘ biomarkers ⓘ clinical trials ⓘ dose-finding studies ⓘ drug development ⓘ medical devices ⓘ pharmaceutical industry ⓘ pharmacokinetics and pharmacodynamics ⓘ post-marketing studies ⓘ preclinical research ⓘ quality-by-design in pharmaceuticals ⓘ real-world evidence ⓘ regulatory science ⓘ safety and efficacy analysis ⓘ |
| targetAudience |
biopharmaceutical researchers
ⓘ
biostatisticians ⓘ pharmaceutical scientists ⓘ statisticians ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Statistics in Biopharmaceutical Research Description of subject: Statistics in Biopharmaceutical Research is a peer-reviewed journal focusing on the development and application of statistical methods in pharmaceutical, biotechnology, and medical product research.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.